Antibody drug cuts moderate Alzheimer’s decline, Swiss biotech cautions over results
August 31, 2021 at 12:08 PM EDT
A Phase 2 trial involving an investigational monoclonal antibody drug, semorinemab, targeting the tau protein, reduced cognitive decline among adults with mild-to-moderate Alzheimer’s disease by about 44%, Swiss biotech AC Immune announced Tuesday.
